# Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

> **NCT05289167** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Northwell Health** · enrollment: 74 (estimated)

## Conditions studied

- Graft-versus-host Disease

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Abatacept
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT05289167
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-13
- **Primary completion:** 2025-12
- **Final completion:** 2027-12
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289167, "Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05289167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*